-
Oct 18, 2022
-
Oct 9, 2022
-
Oct 9, 2022
-
Diagnostics for the Real World Ltd (DRW), innovator of the SAMBA platform for rapid point-of-care detection of infectious diseases, today announces that it has received formal authorisation from the New Zealand government for the sale and distribution of its highly accurate molecular SAMBA II SARS-CoV-2 test, plus its new SAMBA II SARS-CoV-2/FluA/FluB and SAMBA II SARS-CoV-2/RSV multiplex tests – delivering transformative, rapid respiratory infection control capabilities to the country’s healthcare providers.
Oct 4, 2022
-
Oct 3, 2022
-
Absolute Biotech launched today as a unified company joining together leading antibody-centric brands: Absolute Antibody, LSBio, Kerafast, Nordic-MUBio, Everest Biotech and Exalpha from around the world.
Oct 3, 2022
-
Biotium has announced the release of the next-generation Gel-Bright™ Laser Diode Gel Illuminator, offering a better alternative to UV and LED-based gel imaging.
Oct 3, 2022
-
VERICHEM has announced the availability of ready-to-use, multi-level, clinical reference materials for use with Toxicology assays on a wide array of clinical testing systems.
Oct 2, 2022
-
Charles River Avian products, which are used for virus research and to produce veterinary and human vaccines, are now available through the BioIVT Digital Portal.
Oct 2, 2022
-
Deep Breath Intelligence is pleased to announce the launch of DBI-EPIbreath®, a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication (ASM) valproic acid to aid patient management.
Sep 29, 2022
-
Sep 27, 2022
-
Ceryx Medical Limited has announced a partnership with Berlin-based Osypka Medical to develop a heart pacing device that will change the way patients with heart failure and other cardiac conditions are treated.
Sep 26, 2022
-
Here is a link to the press release: https://www.prnewswire.com/news-releases/dispatchhealth-and-pathnostics-initiate-clinical-study-to-compare-guidance-uti-test-to-standard-urine-culture-among-patients-receiving-in-home-care-301634914.html?tc=eml_cleartime
Sep 27, 2022
-
Blue Earth Diagnostics announced that the FDA has accepted its filing for a New Drug Application for 18F-rhPSMA-7.3, an investigational radiohybrid Prostate-Specific Membrane Antigen-targeted (PSMA) PET imaging agent. The submission is for the use of 18F-rhPSMA-7.3 PET for diagnostic imaging of prostate cancer.
Sep 26, 2022
-
Sep 26, 2022
-
Sep 26, 2022
-
Sep 26, 2022
-
Sep 25, 2022
-
Sep 25, 2022
-
This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.
Sep 25, 2022